Carmat SA
PAR:ALCAR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| FR |
|
Carmat SA
PAR:ALCAR
|
6.4m EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
141.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
112.3B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.1B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.4B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.2B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37.3B USD |
Loading...
|
Market Distribution
| Min | -147 400% |
| 30th Percentile | -2.2% |
| Median | 2.6% |
| 70th Percentile | 7.1% |
| Max | 14 243.8% |
Other Profitability Ratios
Carmat SA
Glance View
Carmat SA engages in the developing of implantable orthotropic and biocompatible artificial heart. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 160 full-time employees. The company went IPO on 2010-07-07. The firm is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The firm formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels and Blood Institute, Laboratoire de Recherche Biochirurgicale and others. As of December 31, 2011, a company MATRA DEFENSE held a 30.57% stake in the Company’s shareholdings.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Carmat SA is -737.5%, which is above its 3-year median of -2 443.4%.
Over the last 3 years, Carmat SA’s Net Margin has increased from -2 775.8% to -737.5%. During this period, it reached a low of -15 559.7% on Dec 31, 2022 and a high of -737.5% on Jan 1, 2025.
